RYTM - Latest News
Rhythm Pharmaceuticals, Inc. (RYTM), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $7.97B. Beta to the broader market is 2.13.
The article list below shows the most recent RYTM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent RYTM Headlines
Rhythm Pharmaceuticals (NASDAQ:RYTM) & Senti Biosciences (NASDAQ:SNTI) Head to Head Survey
defenseworld.net - Nov 11, 2026
Senti Biosciences (NASDAQ: SNTI - Get Free Report) and Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) are both healthcare companies, but whic
Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot
seekingalpha.com - Nov 10, 2026
Rhythm Pharmaceuticals maintains strong commercial momentum, with IMCIVREE sales up 79. 5% YoY and a broadening prescriber base in the acquired HO.
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
wsj.com - Nov 4, 2026
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would e
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
globenewswire.com - Nov 4, 2026
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov.
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
seekingalpha.com - Nov 3, 2026
Rhythm Pharmaceuticals, Inc.
How News Affects RYTM Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RYTM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked RYTM news questions
- What is the latest RYTM news headline?
- The most recent RYTM headline (Nov 11, 2026) is "Rhythm Pharmaceuticals (NASDAQ:RYTM) & Senti Biosciences (NASDAQ:SNTI) Head to Head Survey". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the RYTM news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What RYTM news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual RYTM options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.